Wall Street brokerages expect Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings per share of ($0.60) for the current quarter, Zacks reports. Four analysts have provided estimates for Acceleron Pharma’s earnings, with the lowest EPS estimate coming in at ($0.68) and the highest estimate coming in at ($0.57). Acceleron Pharma reported earnings per share of ($0.51) in the same quarter last year, which suggests a negative year-over-year growth rate of 17.6%. The firm is expected to issue its next quarterly earnings report after the market closes on Tuesday, February 27th.
According to Zacks, analysts expect that Acceleron Pharma will report full-year earnings of ($2.65) per share for the current fiscal year, with EPS estimates ranging from ($2.72) to ($2.60). For the next year, analysts forecast that the business will post earnings of ($2.42) per share, with EPS estimates ranging from ($2.69) to ($2.19). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Acceleron Pharma.
Several brokerages have issued reports on XLRN. BidaskClub raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. raised shares of Acceleron Pharma from a “neutral” rating to an “overweight” rating and set a $33.00 price objective for the company in a research report on Monday. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th. HC Wainwright lifted their price objective on shares of Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, November 7th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $55.00 price objective on shares of Acceleron Pharma in a research report on Thursday, January 18th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $44.81.
Large investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in Acceleron Pharma by 10.1% during the fourth quarter. BlackRock Inc. now owns 4,732,135 shares of the biopharmaceutical company’s stock worth $200,832,000 after acquiring an additional 434,123 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Acceleron Pharma by 6.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after buying an additional 116,705 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Acceleron Pharma by 127.2% during the 3rd quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after buying an additional 905,000 shares in the last quarter. State Street Corp boosted its holdings in shares of Acceleron Pharma by 9.4% during the 2nd quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock valued at $34,386,000 after buying an additional 97,199 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its holdings in shares of Acceleron Pharma by 13.0% during the 4th quarter. Farallon Capital Management LLC now owns 1,088,000 shares of the biopharmaceutical company’s stock valued at $46,175,000 after buying an additional 125,000 shares in the last quarter. Institutional investors own 90.13% of the company’s stock.
Shares of Acceleron Pharma (NASDAQ:XLRN) traded up $1.83 during trading hours on Friday, reaching $44.74. 528,400 shares of the company’s stock traded hands, compared to its average volume of 315,087. Acceleron Pharma has a 52 week low of $24.37 and a 52 week high of $46.93. The firm has a market cap of $1,941.04, a P/E ratio of -17.27 and a beta of 1.45.
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Acceleron Pharma Inc (XLRN) to Announce -$0.60 Earnings Per Share” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3225747/zacks-brokerages-anticipate-acceleron-pharma-inc-xlrn-to-announce-0-60-earnings-per-share.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.